Personalis Announces Illumina CSPro Certification for Sequencing

Menlo Park, CA – May 7, 2013 – Personalis announced today that it has successfully completed IlluminaCSPro™ certification for sequencing on HiSeq and MiSeq, gaining entry to an elite group of Illumina genomics service providers globally. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools togenomics centers worldwide.

Illumina CSPro is the collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CSPro participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification, and an on-site audit of the facility and processes.

John West, Personalis’s CEO said, “Our state of the art laboratory is committed to excellence at each step of the process and our deep knowledge of the Illumina technology platform allows us to provide an end to end service that meets the needs of researchers in academia, pharma and clinicians as well. We value Illumina’s commitment to maintain that level of excellence and welcome the opportunity to be a CSPro global partner.”

“Illumina CSPro recognizes organizations that provide customers with industry-leading data quality and service in genetic analysis,” said Karen Possemato, Illumina’s Sr. Director of Corporate Marketing. “Personalis is now a Certified Service Provider in Menlo Park, California able to provide comprehensive sequencing services using Illumina technology. Now that Personalis is a global CSPro partner, we are excited to work with them to make it easier for researchers and clinicians in the US and elsewhere to access the power of Illumina’s genetic analysis technologies.”

About Personalis, Inc.

Personalis, Inc. (www.personalis.com) is a leading precision medicine company focused on advanced NGS-based clinical diagnostic, clinical trial and research services for cancer and inherited genetic disease.  Personalis also provides DNA sequencing and data analysis of human genomes.

The Personalis ACE Exome and Transcriptome technology is designed to obtain the most comprehensive and accurate tumor molecular profile for immuno-oncology applications. The company’s clinical laboratory is GCP compliant, CLIA licensed and CAP accredited.

Media Contact for Personalis:

Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300